(Circulation. 2000;102:e19.)
© 2000 American Heart Association, Inc.
Circulation Electronic Pages |
Department of Cardiology
Director, Sones Cardiac Catheterization Laboratory Cleveland Clinic Foundation, Cleveland, Ohio
| Introduction |
|---|
|
|
|---|
The corrected TIMI frame count (cTFC) has evolved into a standard measurement in many angiographic core laboratories. Although the reproducibility of the cTFC has been demonstrated,1 2 its superiority to TIMI flow grading has remained in question. Work done in our core laboratory has not found the cTFC to have predictive value independent of TIMI flow grading.3 The recent analysis by Gibson et al4 is the first to show that the cTFC correlates with adverse clinical outcomes. However, we are concerned that the analysis examined both cTFC and TIMI flow in separate multivariate models. This approach circumvents the real question of whether the cTFC adds any prognostic information over and above standard TIMI flow grading in a core laboratory setting. If not, the added time and substantial effort needed to measure cTFC cannot legitimately be justified.
| References |
|---|
|
|
|---|
Department of Medicine University of CaliforniaSan Francisco, 3333 California Street, Suite 430, San Francisco, CA 94118
| Introduction |
|---|
|
|
|---|
Unfortunately, despite the fact that this index of flow was highly reproducible in the study by Bhatt et al,R1 it did not achieve statistical significance in relation to a composite clinical end point. The very low rate of ascertainment (66%) in Bhatt et als studyR1 (ie, smaller sample size, type II error) may have negatively impacted their ability to demonstrate a relationship, and it is in sharp contrast to the rate found in a study by the TIMI group (97.2%).R3 In Bhatt et als study,R1 the incidence of adverse outcomes was 10% for TIMI grade 3 flow and 12.7% for TIMI grade 2 flow. This offers minimal risk stratification within patent vessels. In fact, the statistical difference across TIMI flow grades was most likely driven by differences between patent vessels (TIMI grade 2 and 3 flow) versus occluded vessels, which had higher risks of adverse outcomes of 20.5% (TIMI 0 flow) and 25.0% (TIMI 1 flow).R1
Bhatt et alR1 analyzed the CTFC in patients with and without events. It is likely that if the two ends of the CTFC flow spectrum were instead compared in the categorical fashion that mimics the statistical methodology used to compare the TIMI flow grades, then the CTFC would also be related to clinical outcomes. In the TIMI dataset, in-hospital mortality increased from 0.0% (n=0 of 41) in patients with a 90-minute CTFC <14, to 2.7% (n=18 of 658) in patients with a CTFC of 14 to 40, and to 6.4% (n=35 of 549) in patients with a CTFC >40 (P=0.003).R3
Postintervention CTFCs were used in place of 90-minute CTFCs in the study by Bhatt et al.R1 However, as in other studies that examine the time-dependent open-artery hypothesis, we reported the 90-minute CTFCs before the intervention.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |